TABLE 1.
Variables | Mean/number | SD | Range/percentage |
---|---|---|---|
Patients' general characteristics | |||
Total number | 319 | ||
Age | 70.1 | 9.1 | 43–97 year‐old |
Height | 163.8 | 6.0 | 165–179.9 cm |
Weight | 66.8 | 10.8 | 43.1–155.3 kg |
BMI | 24.9 | 3.6 | 17.1–56.6 kg/cm2 |
Prostate volume | |||
Total | 49.1 | 28.6 | 3.3–183 gm |
T‐zone | 20.7 | 15.8 | 0.6–72.4 |
Cancer related parameters | |||
iPSA | 629.5 | 1834.6 | 2.6–23125.5 ng/mL |
ISUP group | |||
1 | 15 | 5.1% | |
2 | 18 | 6.1% | |
3 | 27 | 9.1% | |
4 | 66 | 22.3% | |
5 | 170 | 57.4% | |
DeNovo distant mets | |||
0 | 65 | 20.4% | |
1 | 254 | 79.6% | |
ADT agent | |||
Degarelix | 49 | 15.4% | |
Goserelin acetate | 78 | 24.5% | |
Leuprorelin acetate | 160 | 50.2% | |
Triptorelin | 1 | 0.3% | |
Orchiectomy | 29 | 9.1% | |
1st ARAT agent | |||
Abiraterone acetate | 177 | 55.5% | |
Enzalutamide | 142 | 44.5% | |
Pre‐ or post‐ Chemo setting | |||
Pre‐chemo | 67 | 21.0% | |
Post‐chemo | 85 | 26.6% | |
No chemo | 167 | 52.4% | |
Nadir PSA during ADT | 13.74 | 45.7 | 0–354.1 ng/mL |
PSA when strating ARAT | 214.05 | 606.9 | 0.008–5285.2 ng/mL |
Follow‐up | 79.53 | 50.6 | 11.7–247.2 months |
Abbreviations: ADT = androgen deprivation therapy; ARAT = androgen receptor‐axis‐targeted therapies; BMI = Body Mass Index; ISUP = International Society of Urological Pathology; PSA = prostate‐specific antigen.